Phage library-derived human anti-TETA and anti-DOTA scFv for pretargeting RIT

Hybridoma

Volumn 18, Issue 1, 1999, Pages 13-21

  DeNardo, Sally J ^a,c   DeNardo, Gerald L ^a   Brush, Jennifer ^b   Carter, Paul ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

^c Molecular Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETATE YTTRIUM 90; 1,4,7,11 TETRAAZACYCLOTETRADECANE N,N',N'',N''' TETRAACETATE; 1,4,7,11 TETRAAZACYCLOTETRADECANE N,N',N'',N''' TETRAACETATE COPPER 67; ANTIBODY CONJUGATE; ANTIIDIOTYPIC ANTIBODY; COPPER 67; IMMUNOGLOBULIN FRAGMENT; METAL CHELATE; PEPTIDE LIBRARY; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTIBODY AFFINITY; ANTIGEN BINDING; CANCER IMMUNOLOGY; CONFERENCE PAPER; CONTROLLED STUDY; DNA FINGERPRINTING; DNA SEQUENCE; DRUG STRUCTURE; MOLECULAR CLONING; MOLECULAR MODEL; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN PURIFICATION; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; RESTRICTION MAPPING; SEQUENCE HOMOLOGY;

EID: 0033030385     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1999.18.13     Document Type: Conference Paper

References (59)

1. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, and Stern H: Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;28:126-142.
2. DeNardo GL, DeNardo SJ, Lewis JP, et al.: Treatment of B-cell malignancies in patients using fractionated dose (FD) or maximum tolerated dose (MTD) of I-131 Lym-1 without and with immunophoresis. J Nucl Med 1991;32:921-922.
3. DeNardo SJ, Mirick GR, Kroger LA, et al.: The biologic window for chimeric L6 radioimmunotherapy. Cancer 1994;73(Suppl): 1023-1032.
4. Goodwin DA, Meares CF: Pretargeting: General principles; October 10-12, 1996. Cancer 1997;80:2675-2680.
5. Le Doussal JM, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, and Barbet J: Targeting of indium-111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nuce mice. Cancer Res 1990;50:3445-3452.
6. Hnatowich DJ, Virzi F, and Rusckowski M: Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28: 1294-1302.
7. Paganelli G, Magnani P, Zito F, et al.: Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960-5966.
8. Goodwin DA, Meares CF, and Watanabe N: Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: A model for 90Y radioimmunotherapy. Cancer Res 1994;54:5937-5946.
9. Paganelli G, Chinol M, Grana C, et al.: Therapy trials in cancer patients using an improved 3-step pretargeting approach. In: Radioactive Isotopes in Clinical Medicine and Research. Bergman H, Kroiss H, Sinzinger H. (Eds.). Birkhauser Verlag, Boston, MA, 1997, pp. 513-517.
10. Bos ES, Kuïjpers WH, Meesters-Winters M, et al.: In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer. Cancer Res 1994;54:3479-3486.
11. Axworthy DB, Beaumier PL, Bottino BJ, et al.: Preclinical optimization of pretargeted radioimmunotherapy components: High-efficiency, curative Y-90 delivery to mouse tumor xenografts. Tumor Targeting 1996;2:156-157.
12. Yuan F, Baxter LT, and Jain RK: Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991;51:3119-3130.
13. van Osdol WW, Sung C, Dedrick RL, and Weinstein JN: A distributed pharmacokinetic model of two-step imaging and treatment protocols: Application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin. J Nucl Med 1993;34:1552-1564.
14. Stoldt HS, Aftab F, Chinol M, et al.: Pretargeting strategies for radio-immunoguided tumour localisation and therapy. Eur J Cancer 1997;33:186-192.
15. Zhu H, Jain RK, and Baxter LT: Tumor targeting for radioimmunodetection and radioimmunotherapy. J Nucl Med 1998;39:65-76.
16. Clackson T, Hoogenboom HR, Griffiths AD, and Winter G: Making antibody fragments using phage display libraries. Nature 1991;352:624-628.
17. Chester KA, Begent RH, Robson L, et al.: Phage libraries for generation of clinically useful antibodies. Lancet 1994;343:455-456.
18. Huston JS, McCartney J, Tai MS, et al.: Medical applications of single-chain antibodies. Int Rev Immunol 1993;10:195-217.
19. Vaughan TJ, William AJ, Pritchard K, et al.: Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnol 1996;14:309-314.
20. Carter P, Ridgway J, and Zhu Z: Toward the production of bispecific antibody fragments for clinical applications. J Hematother 1995;4:463-470.
21. Hoogenboom HR: Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol 1997;15:62-70.
22. Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, and Carter P: High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology 1996;14:192-196.
23. Kontermann RE, Wing MG, and Winter G: Complement recruitment using bispecific diabodies. Nat Biotechnol 1997;15:629-631.
24. Wu AM, Chen W, Raubitschek A, et al.: Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimers. Immunotechnology 1996;2:21-36.
25. Epstein AL, Marder RJ, Winter JN, et al.: Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830-840.
26. Moi MK, Meares CF, and DeNardo SJ: The peptide way to macrocyclic bifunctional chelating agents: Systhesis of 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N‴,-N′,N″,N- tetraacetic acid and study of its yttrium (III) complex. J Am Chem Soc 1988;110:6266-6267.
27. Moi MK, Meares CF, McCall MJ, Cole WC, and DeNardo SJ: Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem 1985;148:249-253.
28. McCall MJ, Diril H, and Meares CF: Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug Chem 1990;1:222-226.
29. Kukis DL, DeNardo GL, DeNardo SJ, et al.: Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 1995;55: 878-884.
30. DeNardo SJ, Peng J-S, DeNardo GL, and Mills SL: Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Nucl Med Biol 1986;13:303-310.
31. Kukis DL, Li M, and Meares CF: The selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals. Inorg Chem 1993;32:3981-3982.
32. Penefsky HS: A centrifuged-column procedure for the measurement of ligand binding by beef heart F1. Methods Enzymol 1979;56G:527-530.
33. Griffiths AD, Williams SC, Hartley O, et al.: Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994;13:3245-3260.
34. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, and Winter G: By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991;1:222:581-597.
35. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, and Winter G: Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 1991;19:4133-4137.
36. Harrison JL, Williams SC, Winter G, and Nissim A: Screening of phage antibody libraries. Methods Enzymol 1996;267:83-109.
37. Hawkins RE, Russell SJ, and Winter G: Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 1992;226:889-896.
38. Griffiths AD, Malmqvist M, Marks JD, et al.: Human anti-self antibodies with high specificity from phage display libraries. EMBO J 1993;12:725-734.
39. Abraham R, Buxbaum S, Link J, Smith R, Venti C, and Darsley M: Screening and kinetic analysis of recombinant anti-CEA antibody fragments. J Immunol Methods 1995;183:119-125.
40. Van Regenmortel MH: Use of biosensors to characterize recombinant proteins. Dev Biol Stand 1994;83:143-151.
41. Hodits RA, Nimpf J, Pfistermueller DM, et al.: An antibody fragment from a phage display library competes for ligand binding to the low density lipoprotein receptor family and inhibits rhinovirus infection. J Biol Chem 1995;270:24078-24085.
42. Schier R, Marks JD: Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Hum Antibodies Hybridomas 1996;7:97-105.
43. Malmborg AC, Borrebaeck CA: BIAcore as a tool in antibody engineering. J Immunol Methods 1995;183:7-13.
44. O'Shannessy DJ: Determination of kinetic rate and equilibrium binding constants for macromolecular interactions: A critique of the surface plasmon resonance literature. Curr Opin Biotechnol 1994;5:65-71.
45. Higgins DG, Sharp PM: Clustal: A package for performing multiple sequence alignment on a microcomputer. Gene 1988;73: 237-244.
46. Kukis DL, Diril H, Greiner DP, et al.: A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer 1994;73(Suppl):779-786.
47. DeNardo GL, Kroger LA, DeNardo SJ, et al.: Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 1994;73(Suppl):1012-1022.
48. Deshpande SV, DeNardo SJ, Meares CF, et al.: Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: Labeling and biodistribution in RAJI tumored mice. J Nucl Med 1988;29:217-225.
49. DeNardo GL, DeNardo SJ, Macey DJ, et al.: Quantitative phamacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In: Radiolabeled Monoclonal Antibodies for Imaging and Therapy. Srivastava SC (Ed.). Plenum Publishing Corp, New York, 1988, pp. 293-310.
50. DeNardo SJ, Richman CM, Goldstein DS, Shen S, Salako QA, and Kukis DL: Yttrium-90/Indium-111-DOTA-peptide-Chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res 1997;17:1735-1744.
51. Kaminski MS, Zasadny KR, Francis IR, et al.: Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-465.
52. Buchsbaum DJ, Wessels BW: Radiolabeled antibody tumor dosimetry. In: Cancer Therapy with Radiolabeled Antibodies. Goldenberg DM (Ed.). CRC Press, Ann Arbor, MI, 1994, pp. 21-27.
53. Goldenberg DM, Sharkey RM, Hall TC, et al.: Radioimmunotherapy of B-cell lymphomas with 131-I-labeled LL2 (EPB-2) monoclonal antibody. Antibody Immunoconj Radiopharm 1991;4: 763-769.
54. Jain RK: Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol 1991;60:85-100.
55. Adams GP, Schier R, McCall AM, et al.: What are the determinants of antibody-based targeting? Proceedings Eighty-Ninth Annual Meeting American Association for Cancer Research 1998; 39(Abstract):436.
56. Adams GP, Schier R, Marshall K, et al.: Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998;58:485-490.
57. Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, and Winter G: By-passing immunization: Building high affinity human antibodies by chain shuffling. Bio/Technol 1992;10:779-783.
58. Thompson J, Pope AR, Tung JS, et al.: Affinity maturation of a high-affinity human monoclonal antibody against the third hyper-variable loop of human immunodeficiency virus: Use of phage display to improve affinity and broaden strain reactivity. J Mol Biol 1996;256:77-88.
59. Crameri A, Raillard SA, Bermudez E, and Stemmer WPC: DNA shuffling of a family of genes from diverse species accelerates directed evolution. Nature 1998;391:288-291.